ArticleAmerican journal of hematology2018

Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.

Ian W Flinn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.